Drugs / Flurouracil
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03374852 Background | Aug 2018 → Oct 2019 | pancreatic ductal adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03504423 Background | Nov 2018 → Aug 2021 | pancreatic adenocarcinoma | Cornerstone Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flurouracil | “Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan” NCT03374852 ↗1“Flurouracil at 400 mg/m2 as bolus followed by a 46 hr infusion at 2400mg/m2” NCT03504423 ↗ |
| Known as | 5FU | “Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan” NCT03374852 ↗ |